Jupiter Asset Management Ltd. reduced its holdings in Humana Inc. (NYSE:HUM) by 54.6% during the first quarter, Holdings Channel.com reports. The fund owned 27,474 shares of the insurance provider’s stock after selling 33,079 shares during the quarter. Jupiter Asset Management Ltd.’s holdings in Humana were worth $11,518,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Wade G W & Inc. increased its stake in Humana by 3.1% in the 1st quarter. Wade G W & Inc. now owns 775 shares of the insurance provider’s stock worth $325,000 after acquiring an additional 23 shares during the last quarter. Lindbrook Capital LLC increased its position in shares of Humana by 12.1% during the 1st quarter. Lindbrook Capital LLC now owns 231 shares of the insurance provider’s stock valued at $97,000 after purchasing an additional 25 shares during the last quarter. AdvisorNet Financial Inc increased its position in shares of Humana by 54.5% during the 1st quarter. AdvisorNet Financial Inc now owns 85 shares of the insurance provider’s stock valued at $36,000 after purchasing an additional 30 shares during the last quarter. Wedbush Securities Inc. increased its position in shares of Humana by 3.8% during the 1st quarter. Wedbush Securities Inc. now owns 882 shares of the insurance provider’s stock valued at $370,000 after purchasing an additional 32 shares during the last quarter. Finally, Parallel Advisors LLC increased its position in shares of Humana by 3.0% during the 1st quarter. Parallel Advisors LLC now owns 1,125 shares of the insurance provider’s stock valued at $472,000 after purchasing an additional 33 shares during the last quarter. Institutional investors and hedge funds own 92.11% of the company’s stock.
In related news, insider Christopher H. Hunter sold 5,156 shares of the firm’s stock in a transaction that occurred on Thursday, April 29th. The stock was sold at an average price of $443.76, for a total transaction of $2,288,026.56. Following the completion of the transaction, the insider now owns 8,653 shares of the company’s stock, valued at approximately $3,839,855.28. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Timothy Alan Wheatley sold 8,508 shares of the firm’s stock in a transaction that occurred on Monday, May 3rd. The shares were sold at an average price of $450.59, for a total value of $3,833,619.72. Following the transaction, the insider now directly owns 11,494 shares of the company’s stock, valued at approximately $5,179,081.46. The disclosure for this sale can be found here. 0.40% of the stock is currently owned by corporate insiders.
Humana (NYSE:HUM) last announced its earnings results on Wednesday, April 28th. The insurance provider reported $7.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.21 by $0.46. Humana had a return on equity of 19.08% and a net margin of 4.72%. The firm had revenue of $20.67 billion during the quarter, compared to analyst estimates of $20.42 billion. During the same quarter in the prior year, the company earned $5.40 EPS. The business’s revenue was up 9.2% compared to the same quarter last year. Equities analysts forecast that Humana Inc. will post 21.64 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, July 30th. Stockholders of record on Wednesday, June 30th will be given a $0.70 dividend. This represents a $2.80 annualized dividend and a dividend yield of 0.67%. The ex-dividend date is Tuesday, June 29th. Humana’s dividend payout ratio is currently 14.93%.
Several equities analysts have recently commented on the company. Mizuho increased their price objective on Humana from $462.00 to $480.00 and gave the company a “buy” rating in a research report on Thursday, April 29th. Citigroup increased their target price on Humana from $496.00 to $510.00 in a report on Thursday, April 29th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell increased their target price on Humana from $496.00 to $510.00 and gave the company a “buy” rating in a report on Thursday, April 29th. Oppenheimer increased their target price on Humana from $460.00 to $480.00 and gave the company an “outperform” rating in a report on Thursday, April 29th. Finally, Zacks Investment Research cut Humana from a “hold” rating to a “sell” rating and set a $447.00 target price for the company. in a report on Tuesday, March 30th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $469.00.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Recommended Story: Ex-Dividend
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.